588 related articles for article (PubMed ID: 10804084)
1. VEGF receptor signaling in tumor angiogenesis.
McMahon G
Oncologist; 2000; 5 Suppl 1():3-10. PubMed ID: 10804084
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.
Ellis LM; Takahashi Y; Liu W; Shaheen RM
Oncologist; 2000; 5 Suppl 1():11-5. PubMed ID: 10804085
[TBL] [Abstract][Full Text] [Related]
3. The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma.
Arastéh K; Hannah A
Oncologist; 2000; 5 Suppl 1():28-31. PubMed ID: 10804088
[TBL] [Abstract][Full Text] [Related]
4. Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.
Vajkoczy P; Thurnher A; Hirth KP; Schilling L; Schmiedek P; Ullrich A; Menger MD
Oncologist; 2000; 5 Suppl 1():16-9. PubMed ID: 10804086
[TBL] [Abstract][Full Text] [Related]
5. VEGF in brain tumors.
Machein MR; Plate KH
J Neurooncol; 2000; 50(1-2):109-20. PubMed ID: 11245271
[TBL] [Abstract][Full Text] [Related]
6. The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities.
Siemeister G; Martiny-Baron G; Marmé D
Cancer Metastasis Rev; 1998 Jun; 17(2):241-8. PubMed ID: 9770121
[No Abstract] [Full Text] [Related]
7. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
Shinkaruk S; Bayle M; Laïn G; Déléris G
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
[TBL] [Abstract][Full Text] [Related]
8. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H
Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339
[TBL] [Abstract][Full Text] [Related]
9. von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy.
Harris AL
Oncologist; 2000; 5 Suppl 1():32-6. PubMed ID: 10804089
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor.
Zhu Z; Witte L
Invest New Drugs; 1999; 17(3):195-212. PubMed ID: 10665474
[TBL] [Abstract][Full Text] [Related]
11. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics.
Zhu Z; Bohlen P; Witte L
Curr Cancer Drug Targets; 2002 Jun; 2(2):135-56. PubMed ID: 12188915
[TBL] [Abstract][Full Text] [Related]
12. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
14. Lymphatic versus blood vascular endothelial growth factors and receptors in humans.
Partanen TA; Paavonen K
Microsc Res Tech; 2001 Oct; 55(2):108-21. PubMed ID: 11596156
[TBL] [Abstract][Full Text] [Related]
15. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors.
Schlaeppi JM; Wood JM
Cancer Metastasis Rev; 1999; 18(4):473-81. PubMed ID: 10855790
[TBL] [Abstract][Full Text] [Related]
16. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
Wedge SR; Ogilvie DJ; Dukes M; Kendrew J; Chester R; Jackson JA; Boffey SJ; Valentine PJ; Curwen JO; Musgrove HL; Graham GA; Hughes GD; Thomas AP; Stokes ES; Curry B; Richmond GH; Wadsworth PF; Bigley AL; Hennequin LF
Cancer Res; 2002 Aug; 62(16):4645-55. PubMed ID: 12183421
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects.
Sledge GW
Semin Oncol; 2002 Jun; 29(3 Suppl 11):104-10. PubMed ID: 12138404
[TBL] [Abstract][Full Text] [Related]
18. Regulation of angiogenesis via vascular endothelial growth factor receptors.
Veikkola T; Karkkainen M; Claesson-Welsh L; Alitalo K
Cancer Res; 2000 Jan; 60(2):203-12. PubMed ID: 10667560
[No Abstract] [Full Text] [Related]
19. Angiogenesis-research frontiers. A basic science conference of the New York Academy of Medicine.
Sepp-Lorenzino L; Pan BS
Expert Opin Investig Drugs; 2000 Apr; 9(4):929-35. PubMed ID: 11185425
[TBL] [Abstract][Full Text] [Related]
20. VEGFs, receptors and angiogenesis.
Veikkola T; Alitalo K
Semin Cancer Biol; 1999 Jun; 9(3):211-20. PubMed ID: 10343072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
